Mühl L, Becker E, Müller T, Atreya R, Atreya I, Neurath M, Zundler S (2021)
Publication Type: Journal article
Publication year: 2021
Book Volume: 21
Article Number: 33
Journal Issue: 1
DOI: 10.1186/s12876-021-01604-z
Background: Vedolizumab has become a standard treatment for the inflammatory bowel diseases ulcerative colitis (UC) and Crohn’s disease (CD). However, there is an ongoing debate on the ideal individual treatment algorithms and means to predict treatment response are not routinely established. Aims: We aimed to describe our experiences with vedolizumab at a large German tertiary referral center and to identify clinical predictors of success of vedolizumab treatment. Methods: We performed a retrospective single-center cohort study employing univariable and multivariable analyses as well as Kaplan–Meier analyses of persistence on treatment. Results: 36% and 35% of the patients with UC and CD, respectively, reached clinical remission after 17 weeks. Patients with lower clinical disease activity were more likely to achieve remission. The median persistence on treatment was 33 months for UC and 29 months for CD. Conclusion: Our study confirms that vedolizumab is an efficient option for the treatment of UC and CD. Clinical parameters of disease activity may help to predict the success of treatment.
APA:
Mühl, L., Becker, E., Müller, T., Atreya, R., Atreya, I., Neurath, M., & Zundler, S. (2021). Clinical experiences and predictors of success of treatment with vedolizumab in IBD patients: a cohort study. BMC Gastroenterology, 21(1). https://doi.org/10.1186/s12876-021-01604-z
MLA:
Mühl, Laura, et al. "Clinical experiences and predictors of success of treatment with vedolizumab in IBD patients: a cohort study." BMC Gastroenterology 21.1 (2021).
BibTeX: Download